Table 1 DUB inhibitors
From: The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics
Compound | Reported activity/target | Ref. |
|---|---|---|
Inhibitors containing Michael acceptors | ||
12Δ-PGJ2 | UCHL3 | [139] |
15Δ-PGJ2 | UCHL1 | [139] |
G5 | Broad spectrum DUB inhibition | [140] |
b-AP15 | USP14/UCH37 | [141] |
VLX1570 | USP14/UCH37 | [141] |
AM146, RA-9 and RA-14 | USP2a/USP2b/USP5/USP8 | [143] |
WP1130 | USP5/USP9x/USP14/UCHL1/UCHL5 | [144] |
Eeyarestatin 1 | Ataxin-3 | [145] |
Small inhibitors | ||
AC17 | USP14/UCH37 | [142] |
P022077 | USP7 | [146] |
HBX 41, 108 | USP7 | [148] |
HBX-19, 818 | USP7 | [149] |
HBX-28, 258 | USP7 | [149] |
P5091 | USP7 | [147] |
Cpd 14 | USP7/USP47 | [150] |
P22077 | USP7/USP47 | [151] |
IU1 | USP14 | [139] |
LDN-57444 | UCHL1 | [152] |
LDN91946 | UCHL1 | [153] |
LS1 | UCHL3 | [156] |
PR-619 | Broad spectrum DUB inhibition | [157] |
15-oxospiramilactone (S3) | USP30 | [158] |
Clinical drugs | ||
Pimozide | USP1 | [154] |
Auranofin | proteasome-associated DUBs | [155] |